BOSTON, April 16, 2026

Foundation Medicine, Inc. has announced a major expansion of its oncology diagnostics portfolio through the integration of SAGA Diagnostics’ Pathlight™ molecular residual disease (MRD) platform, following a definitive merger agreement by Roche valued at up to $595 million. The move is set to enhance precision cancer monitoring, treatment decision-making, and early detection of disease recurrence, reinforcing the company’s leadership in advanced genomic diagnostics.

Strategic Integration Strengthens Cancer Monitoring Capabilities

The acquisition of SAGA Diagnostics will enable Foundation Medicine to integrate the Pathlight™ tumor-informed MRD platform into its existing portfolio of diagnostic solutions. This platform is designed to provide ultra-sensitive detection of residual cancer using personalized genomic profiling, allowing clinicians to monitor treatment response and disease recurrence with greater precision.

Pathlight complements Foundation Medicine’s current offerings, including FoundationOne® Monitor and tissue-informed whole genome sequencing MRD tests, creating a comprehensive suite of tools that support end-to-end patient management in oncology. By combining multiple diagnostic approaches, the company aims to deliver more accurate, real-time insights into tumor dynamics, ultimately improving clinical outcomes.

Advanced Genomic Technology Enables Ultra-Sensitive Detection

Advertisement

cGxPJobs Banner

At the core of the Pathlight platform is a proprietary combination of whole genome sequencing (WGS) and digital PCR technology, which enables the identification and tracking of structural variants (SVs)—large-scale genomic alterations associated with cancer progression. This approach allows for highly sensitive detection of minimal residual disease, even at very low levels that traditional methods may miss.

The platform has already demonstrated strong clinical performance in breast and colorectal cancer, and is currently Medicare-covered in the United States for early-stage breast cancer monitoring, highlighting its clinical and commercial relevance. Plans for international expansion are underway, supported by Roche’s global infrastructure and expertise.

Additionally, Foundation Medicine aims to leverage Roche’s AXELIOS sequencing platform and Digital LightCycler® PCR technology to develop a decentralized MRD testing solution, improving accessibility for patients across diverse healthcare settings.

Expanding Role of MRD in Precision Oncology

Molecular residual disease testing is rapidly emerging as one of the most critical tools in precision oncology, enabling clinicians to detect microscopic levels of cancer that remain after treatment. Early detection of MRD allows for timely intervention, personalized treatment adjustments, and improved long-term survival outcomes.

The integration of Pathlight into Foundation Medicine’s portfolio reflects a broader industry trend toward data-driven, biomarker-based cancer management, where genomic insights guide every stage of patient care. By enhancing its MRD capabilities, Foundation Medicine is positioning itself to meet the growing demand for advanced diagnostics that support personalized medicine and clinical decision-making.

Implications for Biopharma and Diagnostic Innovation

This strategic expansion underscores the increasing importance of diagnostic technologies in the biopharma ecosystem, particularly in supporting drug development, clinical trials, and real-world patient monitoring. MRD testing plays a crucial role in evaluating treatment efficacy, stratifying patients, and optimizing therapeutic strategies, making it a key component of modern oncology research.

The collaboration between Foundation Medicine and SAGA Diagnostics also highlights the role of GxP-compliant development, regulatory alignment, and advanced data analytics in bringing innovative diagnostic solutions to market. As precision medicine continues to evolve, the integration of genomics, digital technologies, and real-world data will be essential for improving patient outcomes and advancing healthcare innovation.

The Foundation Medicine expansion through the SAGA Diagnostics MRD platform represents a significant milestone in precision oncology, combining cutting-edge genomic technology, strong clinical validation, and strategic investment to enhance cancer monitoring capabilities. With the growing importance of MRD testing in clinical practice, this move positions the company at the forefront of next-generation diagnostic innovation, driving improved outcomes for patients and supporting the future of personalized cancer care.

Source: Foundation Medicine press release